PANBELA THERAPEUTICS INC by Panbela Therapeutics, Inc. Analyst Price Targets - Benzinga

PANBELA THERAPEUTICS INC by Panbela Therapeutics, Inc.

PBLAOTCEM

Trade with Public

Trade with Public

$1.11

At close: Mar 15, 5:00 PM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare

PANBELA THERAPEUTICS INC by Panbela Therapeutics, Inc. Analyst Price Targets

Wall Street analyst price targets and consensus rating for PANBELA THERAPEUTICS INC by Panbela Therapeutics, Inc. (PBLA).

Price Target Range — 3 Quarters

Analyst Consensus — 2 Analysts

1Buy

1Hold

Consensus RatingBuy# Analysts2Avg. Consensus PT$25Upside to Avg. PT+24999900.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 15, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Neutral	—
Jun 24, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Neutral	—
May 16, 2024	HC Wainwright & Co.	Joseph Pantginis	Downgrade	Buy→Neutral	—
Apr 2, 2024	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$16→$5
Mar 27, 2024	Roth MKM	Jonathan Aschoff	Maintained	Buy	$25
Feb 5, 2024	Roth MKM	Jonathan Aschoff	Maintained	Buy	$500→$25
Dec 18, 2023	Roth MKM	Jonathan Aschoff	Maintained	Buy	$25

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Neutral on Panbela Therapeutics

HC Wainwright & Co. analyst Joseph Pantginis reiterates Panbela Therapeutics (OTC:PBLA) with a Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Panbela Therapeutics

HC Wainwright & Co. analyst Joseph Pantginis reiterates Panbela Therapeutics (OTC:PBLA) with a Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Downgrades Panbela Therapeutics to Neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Panbela Therapeutics (OTC:PBLA) from Buy to Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Panbela Therapeutics, Lowers Price Target to $5

HC Wainwright & Co. analyst Joseph Pantginis maintains Panbela Therapeutics (OTC:PBLA) with a Buy and lowers the price target from $16 to $5.

Benzinga Newsdesk

PRO
Roth MKM Maintains Buy on Panbela Therapeutics, Maintains $25 Price Target

Roth MKM analyst Jonathan Aschoff maintains Panbela Therapeutics (OTC:PBLA) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
Watching Panbela Therapeutics; Roth MKM Says "'Ipsen FDA Approval Of Onivyde In Pancreatic Cancer And Panbelas Earlier Phase 1/1b Results For Sbp-101 For The Same Indication Gives Investors Reason For Optimism.' Reiterate Buy And $25 Price Target"

Benzinga Newsdesk